American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

Effect of Alpelisib on Progression-Free Survival in Breast Cancer Patients with PIK3CA Mutations in the Real-World Setting

ASCO 2021 – Breast Cancer

Alpelisib activity improves real-world progression-free survival in breast cancer patients with PIK3CA mutations when used in combination with fulvestrant compared with fulvestrant alone. Read More ›

Trends in Male Breast Cancer Survival Rates from 1988 to 2017

ASCO 2021 – Breast Cancer

Research indicates no significant improvement in breast cancer–specific survival in male breast cancer in the past 30 years. Read More ›

Association of Poor Prognostic Understanding and Discordance Between Older Patients with Advanced Cancer and Oncologists

ASCO 2021 – Breast Cancer

Prognostic understanding may be associated with hospitalization or hospice use depending on how patients were queried about their prognosis and whether oncologists’ estimates were considered. Read More ›

Implementation of Patient-Reported Remote Symptom Monitoring System in Patients Receiving Intravenous Cancer Therapy

ASCO 2021 – Breast Cancer

Electronic patient-reported outcome remote monitoring of patients receiving parenteral cancer therapy in routine clinical care is feasible. Office intervention may reduce the need for emergency and inpatient services. Read More ›

Cost-Effectiveness of Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC Patients

ASCO 2021 – Lung Cancer

Modeling of the ADAURA trial data showed that 3 years of adjuvant osimertinib was more cost-effective than placebo in EGFR-mutated non–small-cell lung cancer (NSCLC). Read More ›

Utilization of Multigene Assays in Patients with NSCLC

ASCO 2021 – Lung Cancer

The LC-SCRUM-Asia project analysis indicated that utilization of rapid multigene assays in patients with advanced non–small-cell lung cancer (NSCLC) was associated with short turnaround times and high success rates compared with a targeted assay. Read More ›

Prior Authorization Tool Impacts Provider Adherence to Clinical Guidelines and Cost-Savings

ASCO 2021 – Lung Cancer

Provider adherence to National Comprehensive Cancer Network recommendations and implementation of an automated regimen-level prior authorization is associated with lower cost and more efficient oncology care in patients with non–small-cell lung cancer. Read More ›

Repeat Molecular Profiling Detects Actionable Genetic Alterations in Patients with Progressive Lung Cancer

ASCO 2021 – Lung Cancer

The majority of progressing stage IV non–small-cell lung cancer patients with development of resistance to targeted therapies benefit from repeat molecular profiling to detect actionable resistance mechanisms and facilitate clinical trial enrollment. Read More ›

Mobile Lung Cancer Screening in an Underserved Population Finds High Incidence of Concurrent Disease States

ASCO 2021 – Lung Cancer

A mobile computerized tomographic lung screening program detected a high number of incidental concurrent disease findings in a rural underserved high-risk population of heavy smokers. Read More ›

Racial Disparities with Use of Chemotherapy plus Radiotherapy Among Patients with Stage III NSCLC

ASCO 2021 – Lung Cancer

Analysis of the National Cancer Database indicates that a lower proportion of black patients with locally advanced, stage III, non–small-cell lung cancer (NSCLC) receive concurrent chemotherapy plus radiotherapy compared with white patients. Read More ›

American Society of Clinical Oncology (ASCO)

Page 8 of 33